News

Prior to becoming a public company, Livzon was a principal investor in the $36m private financing round EPIRUS that closed in April 2014. EPIRUS’ Remicade biosimilar BOW015 (infliximab)

The joint laboratory will focus on the discovery and development of new biologic cancer treatments over an initial five-year period. Under the deal, scientists from both organisations will

The oversubscribed round was led by New Enterprise Associates (NEA), and additional new investors participating included OrbiMed Advisors LLC, Wellington Management Company, LLP, Fidelity Biosciences, Foresite Capital Management,

An international group of public and private organisations is collaborating to accelerate development of an innovative heat-stable and low-cost inhaled form of oxytocin to manage postpartum hemorrhage in

Crohn’s disease is a type of inflammatory bowel disease (IBD) which involves the end of the small intestine and the large intestine. The FDA approval represents the eighth

The new unit will be aimed at identifying new approaches and targets for obesity treatments while increasing the scientific understanding of existing obesity targets. Initially, around ten people

In addition, the companies have formed a partnership that will leverage the strengths of both organizations to identify and develop new drugs. The five-year investment gives Takeda the

Earlier, Pfizer agreed to make an upfront payment of $225m to InnoPharma and up to $135m of contingent milestone payments. InnoPharma has developed capabilities in complex injectable delivery

Actavis’ ANDA product is a generic version of Purdue Pharma’s Butrans, which is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment